{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/6a0edab4a9d3d2ec14983bf2?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Why End-to-End CDMOs Matter More Than Ever - SmaBio Labs CEO","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1779358325977-0244454a-9a1f-4ec7-a9e1-eb7b44d86f62.jpeg?height=200","description":"<p>95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.</p><p><br></p><p>What does it take to build a CDMO designed around speed, integration, and true scientific collaboration?</p><p><br></p><p>This week on Making It In Manufacturing, Harry Sloan sat down with LakshmiDevi Ethirajan, Co-Founder &amp; CEO of SmaBioLabs, with 25+ years of experience spanning big pharma, small pharma, and CDMO leadership roles across drug development and manufacturing.</p><p><br></p><p>In this episode, LakshmiDevi Ethirajan covers:</p><p><br></p><p>• How a background in pharmacy and pharmaceutical development led to the creation of SmaBioLabs and the vision behind building a fully integrated CDMO</p><p><br></p><p>• Why bringing discovery, formulation development, and analytical services together under one roof reduces risk and improves program execution</p><p><br></p><p>• The importance of speed and flexibility in pharmaceutical development, including why projects at SmaBioLabs begin within two weeks of contract signing</p><p><br></p><p>• How technical integration between discovery scientists and formulation teams supports complex molecules and improves development outcomes</p><p><br></p><p>• The long-term vision for SmaBioLabs, including commercial manufacturing expansion and becoming a complete end-to-end partner for sponsors</p><p><br></p><p>If you are involved in pharmaceutical manufacturing, biotech growth, CDMO strategy, or drug development leadership, this conversation offers a practical perspective on building scalable scientific partnerships in a rapidly evolving industry.</p><p><br></p><p>Follow ARTO</p><p><br></p><p>LinkedIn: https://www.linkedin.com/company/artotalent</p><p>Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng</p><p>Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&amp;utm_source=qr</p><p>TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&amp;_r=1</p><p>Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575</p><p>Website: https://arto-talent.com/</p><p>Youtube: https://www.youtube.com/@artotalent</p><p><br></p><p>LakshmiDevi Ethirajan</p><p>Co-Founder &amp; CEO of SmaBioLabs</p><p>LinkedIn: https://www.linkedin.com/in/lakshmidevi-ethirajan/</p><p><br></p><p>Harry Sloan</p><p>BD CDMO Lead at ARTO</p><p>LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/</p><p><br></p><p>Timestamps:</p><p><br></p><p>00:00 Introduction</p><p>00:14 LakshmiDevi Ethirajan’s journey into pharmaceuticals</p><p>01:07 Why sponsor and CDMO alignment matters</p><p>02:27 Building an end-to-end CDMO model</p><p>03:58 Speed and flexibility in drug development</p><p>05:00 Supporting complex molecules through integration</p><p>06:46 The meaning behind the SmaBio Labs name</p><p>07:56 Growth plans and commercial manufacturing ambitions</p><p>08:51 Standing out in the competitive CDMO market</p><p>10:17 The North Carolina biotech ecosystem</p><p>12:37 Leadership, culture, and patient impact</p><p>13:53 Closing remarks</p><p><br></p><p>#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDevelopment #Biotech #LifeSciences #ManufacturingLeadership #PharmaIndustry #Biotechnology #DrugDiscovery #AnalyticalServices #FormulationDevelopment</p>","author_name":"ARTO Talent"}